EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population

Kensuke Kawai iD, Eunyeong Choe, Louis Ferrari iD, Kyoung Heo iD, Seung Bong Hong iD, Huapin Huang iD, Koji Iida iD, Yong Heui Jeon iD, Jiwon Jung, Marc Kamin, Ji Hyun Kim iD, Myung Won Kim und 8 weitere

Epilepsia · 2026-03 · 67 (3) · 1235-1245

DOI: 10.1111/epi.70012 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, online erschienen am 13.11.2025. Verfasst von Kensuke Kawai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Jichi Medical University, Shimotsuke, Japan. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Chlorophenols, Seizures. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SK Biopharmaceuticals, SK Life Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To examine early responses to cenobamate therapy using prospective data from a dose–response study in Asian patients with focal seizures (YKP3089C035, C035) that employed a titration regimen starting at 12.5 mg/day.

Methods

In Study C035, adults 18–70 years of age with uncontrolled focal seizures despite treatment with 1–3 antiseizure medications were randomized 1:1:1:1 to receive placebo or adjunctive cenobamate 100, 200, or 400 mg/day. The 24‐week double‐blind study included an 18‐week titration and 6‐week maintenance phase. During the first 8 weeks of titration (“early titration phase”), all cenobamate patients received the same dosing regimen: 12.5 mg/day for 2 weeks, 25 mg/day for 2 weeks, 50 mg/day for 2 weeks, and 100 mg/day for 2 weeks. Change in seizure frequency from baseline and responder rates were assessed at these 2‐week intervals for combined cenobamate dose groups vs placebo. Analyses were performed on the modified intent‐to‐treat maintenance (MITT‐M) population (≥1 study drug dose and seizure data in the maintenance phase); all patients completed early titration.

Results

Of 519 patients randomized, 446 were included in the MITT‐M population (placebo n = 117, cenobamate n = 329). During Weeks 1–2, 3–4, 5–6, and 7–8 of titration, cenobamate patients experienced a median reduction in 28‐day seizure frequency of 16.0% (vs 20.0% placebo, p = .81), 27.3% (vs 22.2% placebo, p = .42), 42.9% (vs 15.4% placebo, p = .002), and 55.6% (vs 20.0% placebo, p < .001), respectively. During Weeks 5–6 and 7–8, the 100% responder rates for cenobamate 50 and 100 mg/day were 17.0% (vs 12.8% placebo, p = .29) and 26.7% (vs 8.5% placebo, p < .001), respectively. Significance Statistically significant responses to cenobamate treatment occurred within the first 8 weeks of titration, including a 42.9% median reduction in 28‐day seizure frequency (Weeks 5–6) and a seizure‐free rate of 26.7% (Weeks 7–8). These data show that substantial seizure reductions occurred in many patients early during cenobamate titration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsCarbamatesChlorophenolsSeizuresEpilepsies, PartialTetrazolesHumansDouble-Blind MethodMaleAdultFemaleMiddle AgedYoung AdultAgedAdolescentTreatment OutcomeDose-Response Relationship, DrugProspective StudiesDrug Therapy, CombinationAsian People

Stichwörter der Autor:innen

antiseizure medicationefficacyepilepsyrefractorytitration

Substanzen

AnticonvulsantsCenobamateCarbamatesChlorophenolsTetrazoles

Autor:innen und Institutionen

  • Jichi Medical University, Shimotsuke, Japan.
  • SK Biopharmaceuticals Co., Ltd., Seongnam, Korea.
  • SK Life Science, Inc., Paramus, New Jersey, USA.
  • Yonsei University College of Medicine, Seoul, Korea.
  • Epilepsy & Sleep Center, St. Peter's General Hospital, Seoul, Korea.
  • Fujian Medical University Union Hospital, Fuzhou, China.

ORCID-Profile: Kensuke Kawai, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Huapin Huang, Koji Iida, Yong Heui Jeon, Ji Hyun Kim, Sang Kun Lee, Songqing Pan, Jungshin Park, Pranoti Pradhan, William E Rosenfeld, Huiqin Xu, Takamichi Yamamoto, Sunita N Misra

Förderung

  • SK Biopharmaceuticals
  • SK Life Science

Zitieren

APA

Kawai, K., Choe, E., Ferrari, L., Heo, K., Hong, S. B., Huang, H., Iida, K., Jeon, Y. H., Jung, J., Kamin, M., Kim, J. H., Kim, M. W., Lee, S. K., Pan, S., Park, J., Pradhan, P., Rosenfeld, W. E., Xu, H., Yamamoto, T., & Misra, S. N. (2026). Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population. Epilepsia, 67(3), 1235-1245. https://doi.org/10.1111/epi.70012

Vancouver

Kawai K, Choe E, Ferrari L, Heo K, Hong SB, Huang H, et al. Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population. Epilepsia. 2026;67(3):1235-1245. doi:10.1111/epi.70012

BibTeX
@article{Kawai2026,
  author = {Kawai, Kensuke and Choe, Eunyeong and Ferrari, Louis and Heo, Kyoung and Hong, Seung Bong and Huang, Huapin and Iida, Koji and Jeon, Yong Heui and Jung, Jiwon and Kamin, Marc and Kim, Ji Hyun and Kim, Myung Won and Lee, Sang Kun and Pan, Songqing and Park, Jungshin and Pradhan, Pranoti and Rosenfeld, William E and Xu, Huiqin and Yamamoto, Takamichi and Misra, Sunita N},
  title = {Early response rates with adjunctive cenobamate in uncontrolled focal seizures: Prospective analysis of a randomized, double‐blind, placebo‐controlled study in a multinational Asian population},
  journal = {Epilepsia},
  year = {2026},
  volume = {67},
  number = {3},
  pages = {1235--1245},
  doi = {10.1111/epi.70012}
}
Kostenlos starten →